Health Condition 1: J849- Interstitial pulmonary disease, unspecified
Conditions
Interventions
Intervention1: Formoterol and beclomethasone: Formoterol fumarate (6mcg) and beclomethasone dipropionate (100mcg)- combination- via Extra fine particle Metered dose inhaler with spacer - Twice a day f
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: All diagnosed patients of interstitial lung diseases attending the ILD special clinic with small airway disease as diagnosed by FEF25-75% <65%.
Exclusion criteria
Exclusion criteria: Patients unwilling to participate in the study, Coexisting other diagnoses that may cause an obstructive pattern in PFT, Patients are unable to use the MDI as trained, Within one month of acute exacerbation or requiring an increase in steroid /immunosuppression dose during the study period of 8 weeks, Within one month of any upper/ lower respiratory tract infections requiring treatment modifications, Patients not giving consent for the study, Patients having contraindications for the use of inhaled corticosteroids and Patients who are actively smoking.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in FEF 25%-75% with the addition of extra fine particle inhaled corticosteroids and bronchodilators in patients of interstitial lung diseases associated with small airway diseaseTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To measure the level of improvement in symptom scores (K-BILD) with addition of ICS and inhaled LABA to the standard treatment regimen in patients of various interstitial lung diseasesTimepoint: 8 weeks;Change in RV/TLC with the addition of extra fine particle inhaled corticosteroids and bronchodilators in patients of interstitial lung diseases associated with small airway diseaseTimepoint: 8 weeks | — |
Countries
India
Contacts
Public ContactDr Naveen Dutt
All India Institute of Medical Sciences
Outcome results
None listed